Search research articles
Contact Us
Filters
Showing results (1-10 of 30) with videos related to
Page
of 3
Sort By:
The Journal of Prevention of Alzheimer'S Disease
|
May 29, 2020
Editorial: Screening for Mild Cognitive Impairment: There Is the Will but Is There a Way?
J E Galvin
Veterinary Immunology and Immunopathology
|
October 1, 1994
Bacterial immunogens and protective immunity in swine
M J Wannemuehler, J E Galvin
Journal of Medical Microbiology
|
March 25, 1998
Morphologic and temporal characterisation of lesions in an enhanced murine model of Serpulina hyodysenteriae infection
D L Hutto, J E Galvin, M J Wannemuehler
Archives of Neurology
|
February 15, 2001
Synucleinopathies: clinical and pathological implications
J E Galvin, V M Lee, J Q Trojanowski
The Journal of Clinical Investigation
|
July 21, 2000
Cytotoxic mAb from rheumatic carditis recognizes heart valves and laminin
J E Galvin, M E Hemric, K Ward, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 11, 1999
Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein
J E Galvin, K Uryu, V M Lee, et al.
Molecular Immunology
|
April 3, 2001
Molecular analysis of cross-reactive anti-myosin/anti-streptococcal mouse monoclonal antibodies
N M Mertens, J E Galvin, E E Adderson, et al.
Experimental Neurology
|
March 22, 2001
Differential expression and distribution of alpha-, beta-, and gamma-synuclein in the developing human substantia nigra
J E Galvin, T M Schuck, V M Lee, et al.
Biologicals : Journal of the International Association of Biological Standardization
|
August 3, 2001
Pasteurella multocida toxin type D serological assay as an alternative to the toxin neutralisation lethality test in mice
D L Finco-Kent, J E Galvin, B T Suiter, et al.
International Journal of Clinical Practice
|
February 17, 2015
Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease
G Alva, J L Cummings, J E Galvin, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 30) with videos related to
Sort By:
Page
of 3
The Journal of Prevention of Alzheimer'S Disease
|
May 29, 2020
Editorial: Screening for Mild Cognitive Impairment: There Is the Will but Is There a Way?
J E Galvin
Veterinary Immunology and Immunopathology
|
October 1, 1994
Bacterial immunogens and protective immunity in swine
M J Wannemuehler, J E Galvin
Journal of Medical Microbiology
|
March 25, 1998
Morphologic and temporal characterisation of lesions in an enhanced murine model of Serpulina hyodysenteriae infection
D L Hutto, J E Galvin, M J Wannemuehler
Archives of Neurology
|
February 15, 2001
Synucleinopathies: clinical and pathological implications
J E Galvin, V M Lee, J Q Trojanowski
The Journal of Clinical Investigation
|
July 21, 2000
Cytotoxic mAb from rheumatic carditis recognizes heart valves and laminin
J E Galvin, M E Hemric, K Ward, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 11, 1999
Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein
J E Galvin, K Uryu, V M Lee, et al.
Molecular Immunology
|
April 3, 2001
Molecular analysis of cross-reactive anti-myosin/anti-streptococcal mouse monoclonal antibodies
N M Mertens, J E Galvin, E E Adderson, et al.
Experimental Neurology
|
March 22, 2001
Differential expression and distribution of alpha-, beta-, and gamma-synuclein in the developing human substantia nigra
J E Galvin, T M Schuck, V M Lee, et al.
Biologicals : Journal of the International Association of Biological Standardization
|
August 3, 2001
Pasteurella multocida toxin type D serological assay as an alternative to the toxin neutralisation lethality test in mice
D L Finco-Kent, J E Galvin, B T Suiter, et al.
International Journal of Clinical Practice
|
February 17, 2015
Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease
G Alva, J L Cummings, J E Galvin, et al.
Page
of 3